Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals

Philip M. Grant, Douglas Kitch, Grace A. McComsey, Ann C. Collier, Susan L. Koletar, Kristine M. Erlandson, Michael T. Yin, Benedetta Bartali, Belinda Ha, Kathy Melbourne, Todd T Brown

Research output: Contribution to journalArticle


We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5 years after antiretroviral therapy (ART) initiation and HIV-uninfected controls. HIV-infected individuals (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96 weeks of ART. Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate of decline in HIV-uninfected individuals at the lumbar spine but not at the hip. In HIV-infected individuals after 96 weeks, no HIV-or treatment-related characteristic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at both lumbar spine and hip.

Original languageEnglish (US)
Pages (from-to)607-611
Number of pages5
JournalJournal of Infectious Diseases
Issue number4
StatePublished - Aug 15 2016



  • Administration and dosage
  • Adverse effects
  • Anti-HIV agents
  • Bone density
  • Drug therapy/virology
  • HIV infections

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Grant, P. M., Kitch, D., McComsey, G. A., Collier, A. C., Koletar, S. L., Erlandson, K. M., Yin, M. T., Bartali, B., Ha, B., Melbourne, K., & Brown, T. T. (2016). Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals. Journal of Infectious Diseases, 214(4), 607-611. https://doi.org/10.1093/infdis/jiw204